Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733029 · ClinicalTrials.gov registry record · Phase 2
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02733029 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 8 participants.
The verdict
NCT02733029, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility and efficacy of detecting kidney transplant rejection using contrast enhance ultrasonography with the contrast agent Sonazoid.
Interventions
- DRUG Sonazoid
- DEVICE contrast enhanced ultrasonography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02733029
The ClinicalTrials.gov registry entry for NCT02733029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sonazoid is the first listed.
NCT02733029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02733029 about?
NCT02733029 is a clinical study titled "Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection". The purpose of this study is to determine the feasibility and efficacy of detecting kidney transplant rejection using contrast enhance ultrasonography with the contrast agent Sonazoid.
What is the current status of trial NCT02733029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-05-30. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT02733029?
The interventions under investigation include: Sonazoid (DRUG), contrast enhanced ultrasonography (DEVICE).
Who is sponsoring clinical trial NCT02733029?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.